On February 4, 2013 the U.S. Food and Drug Administration approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection). Doxorubicin hydrochloride liposome injection is currently on the FDA’s drug shortage list. For products on the shortage list, the FDA’s Office of Generic Drugs is using a priority review system to […]
On January 29, 2012 the U.S. Food and Drug Administration approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density […]
COMBIVENT (ipratropium bromide and albuterol sulfate) – an inhaled combination of an anticholinergic (ipratropium) and a beta adrenergic agonist (albuterol) commonly used to chronic obstructive pulmonary disease (COPD). Ipratropium exerts its clinical effect by antagonizing the affects of acetylcholine, thereby preventing or relieving bronchospasm. Albuterol is a beta agonist which exerts its effect by relaxing […]
ProAir HFA (albuterol sulfate) – a metered dose beta agonist inhaler commonly used to treat asthma. The pharmacologic effects of albuterol sulfate are attributable to activation of beta2-adrenergic receptors on airway smooth muscle. Activation of beta2-adrenergic receptors leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3′, 5’-adenosine monophosphate […]